MedTrace Logo

A Study to Evaluate Fenofibrate Combination With Statin in Chinese Patients With Dyslipidemic

NCT01462877 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 506

Last updated 2015-03-17

Study results available
· View outcomes & findings →

Summary

Atherogenic dyslipidemia includes patients who have coronary heart disease (CHD) or CHD risk equivalents, whose TG level is not adequately controlled after statin monotherapy. According to the published ESC/EAS consensus, fibrate is suggested to be added to this type of patient who has insufficient improvement. The purpose of the study is to evaluate the efficacy on lipid control and the safety of adding fenofibrate in patients on a background of statin treatment.

Conditions

Interventions

DRUG

fenofibrate

Fenofibrate Capsule 200mg qd orally

Sponsors & Collaborators

  • Rundo International Pharmaceutical Research & Development Co.,Ltd.

    collaborator INDUSTRY

  • Abbott

    lead INDUSTRY

Principal Investigators

  • Lyra Xie, MD · Abbott

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2014-02-28
Completion
2014-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01462877 on ClinicalTrials.gov